Blueprint Lays Out Path To Early Approval In Small GIST Population
Executive Summary
Blueprint Medicines will pursue an accelerated path to approval for its newly designated breakthrough therapy BLU-285 in the treatment of gastrointestinal stromal tumors in a small subset of patients.
You may also be interested in...
Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Blueprint Medicines Aims For Genomically Defined GIST Indication With Avapritinib NDA
Kinome-focused Blueprint Medicines plans to follow up its first NDA, for all lines of therapy in patients with exon 18 mutant GIST or fourth-line use in non-genomically selected patients, with submissions for third-line GIST and advanced systemic mastocytosis in 2020.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.